Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome

Objectives: Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instill...

Full description

Bibliographic Details
Main Authors: R. Waked, J. Choucair, N. Chehata, E. Haddad, G. Saliba
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405579420300073
id doaj-92737d143b1c4a3d8b0067747de20005
record_format Article
spelling doaj-92737d143b1c4a3d8b0067747de200052020-11-25T02:25:24ZengElsevierJournal of Clinical Tuberculosis and Other Mycobacterial Diseases2405-57942020-05-0119Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcomeR. Waked0J. Choucair1N. Chehata2E. Haddad3G. Saliba4Department of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, Lebanon; Corresponding author.Coordinator of the Infectious Diseases department, Saint Joseph University, Beirut, LebanonDepartment of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, LebanonDepartment of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, LebanonDepartment of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, LebanonObjectives: Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instillation for bladder tumor encountered at our institution for the past 5 years. Methods: Medical records of a tertiary teaching hospital, located in Beirut, Lebanon, were retrospectively analyzed from June 2014 to June 2019 searching for severe related complications of BCG. A comprehensive review of articles on this subject was conducted. Results: The incidence of severe systemic adverse events related to BCG instillation was 1.5% (5 out of 332 patients). A total of five patients were found to have a severe BCG related complication, with fever, chills, and irritative urinary signs being the most frequent symptoms. All patients received antituberculosis therapy (Isoniazid, Rifampin and Ethambutol). Two were put on add-on corticosteroids. Three patients had a computed tomography scan image in favor of an infection. Two patients had a favorable outcome, three patients died. Conclusion: BCG severe adverse events were mostly seen in patients with a traumatic instillation. Treatment used at our institution was similar to most cases reported in the literature. A standardized diagnostic and treatment approach should be implemented to help physicians tackle these life-threatening complications.http://www.sciencedirect.com/science/article/pii/S2405579420300073Mycobacterial infectionIntravesical Bacillus Calmette-GuérinBacillus Calmette-GuerinUrothelial bladder cancerSevere complicationTreatment protocol
collection DOAJ
language English
format Article
sources DOAJ
author R. Waked
J. Choucair
N. Chehata
E. Haddad
G. Saliba
spellingShingle R. Waked
J. Choucair
N. Chehata
E. Haddad
G. Saliba
Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Mycobacterial infection
Intravesical Bacillus Calmette-Guérin
Bacillus Calmette-Guerin
Urothelial bladder cancer
Severe complication
Treatment protocol
author_facet R. Waked
J. Choucair
N. Chehata
E. Haddad
G. Saliba
author_sort R. Waked
title Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
title_short Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
title_full Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
title_fullStr Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
title_full_unstemmed Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
title_sort intravesical bacillus calmette-guérin (bcg) treatment's severe complications: a single institution review of incidence, presentation and treatment outcome
publisher Elsevier
series Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
issn 2405-5794
publishDate 2020-05-01
description Objectives: Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instillation for bladder tumor encountered at our institution for the past 5 years. Methods: Medical records of a tertiary teaching hospital, located in Beirut, Lebanon, were retrospectively analyzed from June 2014 to June 2019 searching for severe related complications of BCG. A comprehensive review of articles on this subject was conducted. Results: The incidence of severe systemic adverse events related to BCG instillation was 1.5% (5 out of 332 patients). A total of five patients were found to have a severe BCG related complication, with fever, chills, and irritative urinary signs being the most frequent symptoms. All patients received antituberculosis therapy (Isoniazid, Rifampin and Ethambutol). Two were put on add-on corticosteroids. Three patients had a computed tomography scan image in favor of an infection. Two patients had a favorable outcome, three patients died. Conclusion: BCG severe adverse events were mostly seen in patients with a traumatic instillation. Treatment used at our institution was similar to most cases reported in the literature. A standardized diagnostic and treatment approach should be implemented to help physicians tackle these life-threatening complications.
topic Mycobacterial infection
Intravesical Bacillus Calmette-Guérin
Bacillus Calmette-Guerin
Urothelial bladder cancer
Severe complication
Treatment protocol
url http://www.sciencedirect.com/science/article/pii/S2405579420300073
work_keys_str_mv AT rwaked intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome
AT jchoucair intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome
AT nchehata intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome
AT ehaddad intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome
AT gsaliba intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome
_version_ 1724851533847199744